S&P 500, Nasdaq Extend Win Streaks

[ad_1] Major stock indexes ended mostly higher Wednesday, building on a long run of gains.  The S&P 500 added 0.1%, notching an eighth-straight session in the green. The Nasdaq Composite…

First Pill for Postpartum Depression Is Approved by FDA

[ad_1] The first pill to treat post-pregnancy depression will soon be available, after the Food and Drug Administration approved it. [ad_2] Source link

Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet

[ad_1] The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity. [ad_2] Source link

Alzheimer’s Blockbuster Is Coming, but Slowly

[ad_1] Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. [ad_2] Source link

Medicare Plans to Cover Alzheimer’s Drugs

[ad_1] Biogen and Eisai’s Leqembi is up for full approval this summer. [ad_2] Source link

Eli Lilly Results Signal Arrival of Blockbuster New Drug Class

[ad_1] Share Listen (2 min) [ad_2] Source link

Eli Lilly Is Priced for Perfection in the Obesity Market

[ad_1] The company has outperformed its pharma peers in recent years, but its valuation leaves little room for error. [ad_2] Source link

Biogen Boss Turns Corner on Alzheimer’s Miscues

[ad_1] The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm. [ad_2] Source link

FDA Seeks More Data on Lilly’s Alzheimer’s Drug Candidate

[ad_1] Business Health Care Health Setback could delay potential commercial introduction by at least several months [ad_2] Source link

A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.

[ad_1] Pharmaceutical companies could try to blunt the limits on future price increases. [ad_2] Source link